Due to the Omicron variety spreads, the Central Drugs Standard Control Organization and Ministry of Health and Family
Welfare have approved two new vaccinations and antiviral medication to protect individuals from Covid-19.
Image credit: India Today
Molnupiravir, developed by Merck & Co. and Ridgeback Biotherapeutics LP, the first anti-viral Covid-19 pill, was approved by the Indian drug regulator on 28th December 2021.
13 Indian drug manufacturers will produce the medication domestically, according to Union Health Minister Mansukh Mandaviya.
The medicine will be manufactured by Dr Reddy Laboratories, Cipla, Natco Pharma, Optimus Pharma Pvt Ltd, Stride, and Hetero, among other prominent pharmaceutical companies.
Usage of Molnupiravir to Treat SARS-CoV-2
Molnupiravir (MK-4482, EIDD-2801) has been repurposed for a cause!
So the medicine was developed to treat influenza not covid. But the medicine “Molnupiravir (MK-4482, EIDD-2801)” can prevent the SARS-CoV-2 virus from replicating further by introducing errors into its genetic code.
The drug is given orally in four 200 milligram capsules every 12 hours for five days, totaling 40 capsules. Molnupiravir should not be used for more than five days in a row, according to the USFDA.
Molnupiravir was cleared in “certain adults” in the United States on December 23.
Molnupiravir: Restrictions and Conditions
· The medicine sold by retail under the supervision of medical specialists.
· The recommended dose is 800mg twice daily for five days.
· Molnupiravir should not be used for more than five days in a row, according to the USFDA.
· Molnupiravir is not approved for use in patients younger than 18 years old because it can disrupt bone and cartilage formation.
Disclaimer: This news story has been edited by DNW staff as per DNW editorial guidelines and is published from a syndicated feed.
Commentaires